紅太陽(000525.SZ):控股股東擬與第三方商談籌劃轉讓部分股權事項
格隆匯11月7日丨紅太陽(000525.SZ)公佈,公司於2019年11月7日收到公司控股股東南京第一農藥集團有限公司(“南一農集團”)的通知,為整合更多資源,加快和支持公司的高質量發展,強化公司的戰略目標得以實現,加快產業和資本的融合,維護公司及股東利益,南一農集團擬與第三方商談籌劃轉讓部分股權事項,引進新的戰略投資者實現共贏。
此次股權轉讓事項尚處在籌劃過程中,具體實施方案仍在研究和商談中,最終實施情況存在不確定性;此次股權轉讓事項不涉及公司控股股東及實際控制人變更;此次股權轉讓事項不會對公司目前的生產經營情況造成影響,不存在損害公司及中小股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.